Details of PD Patients at Time of Progression to HY Stage 2
| Patient no. | Interval (y)* | % Increase of UPDRS† | Levodopa (mg/d) | Dopamine agonist (mg/d) | Anticholinergic agent (mg/d) | Selegiline (mg/d) |
| 1 | 5 | 73 | 200 | 0.5 | 4 | — |
| 2 | 5 | 100 | 100 | 0.5 | 4 | — |
| 3 | 2 | 71 | 200 | 0.75 | 4 | 5 |
| 4 | 3 | 38 | 100 | 0.5 | 4 | — |
| 5 | 1.8 | 75 | 200 | 0.75 | 4 | 5 |
| 6 | 4 | 65 | 100 | 0.5 | 4 | — |
| 7 | 4.4 | 33 | 100 | 0.5 | 4 | — |
| 8 | 3 | 33 | 100 | 0.5 | 4 | — |
| 9 | 2 | 40 | 100 | 0.5 | 4 | — |
| 10 | — | — | — | — | — | — |
| 11 | 1.5 | 48 | 200 | 0.75 | 4 | 5 |
| 12 | 0.5 | 44 | 200 | 0.75 | 4 | 5 |